HY-10992 Search Results


azd7762  (MedChemExpress)
95
MedChemExpress azd7762
Figure 5: CX-5461 combination with a dual CHK1/CHK2 inhibitor induces cancer cell death of Tp53-null (Tp53−/−) Eμ-Myc lymphoma cells in vitro and in vivo. (A) Cell cycle analysis using BrdU incorporation (upper panels) and PI staining for DNA content (lower panels) was performed of p53 wild-type (Tp53 Wt) and (Tp53−/−) Eμ-Myc lymphoma cells following 24-hour treatment with vehicle, 100 nM CX-5461, 30 nM <t>AZD7762</t> (CHK1/2i) or combined 100 nM CX-5461/30 nM CHK1/2i. Analysis was performed as in Figure 2A (representatives of n = 3). (B) Western blotting analysis of phosphorylated and total protein levels of p53 and CHK1 in Tp53 Wt and Tp53−/− Eμ-Myc lymphoma cells following 30 min treatment with CX-5461 as indicated. Actin levels were used as a loading control. (C) Percentages of live Tp53-/- Eμ-Myc lymphoma cells (Annexin V –ve/ PI –ve) cells treated as in (A) (n = 3), error bars represent mean ± s.e.m., **p-value < 0.01 compared to corresponding CX-5461 treated samples. (D) CX-5461 combination with CHK1/2i leads to improved therapeutic benefit in treating transplanted Tp53−/− Eμ-Myc lymphoma cells in vivo. Kaplan-Meier curves showing increased survival of mice transplanted with Tp53−/− Eμ-Myc lymphoma (clone 3228) treated daily with 20 mg/kg AZD7762 (CHK1/2i) every weekday, CX-5461 at 30 mg/kg every third day or combined CX-5461+CHK1/2i (***p < 0.0001; n = 6 in every treatment group). Treatment period is indicated by the grey area.
Azd7762, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/HY-10992/AZD-7762/pm27391441-227-0-1
Average 95 stars, based on 1 article reviews
azd7762 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

Image Search Results


Figure 5: CX-5461 combination with a dual CHK1/CHK2 inhibitor induces cancer cell death of Tp53-null (Tp53−/−) Eμ-Myc lymphoma cells in vitro and in vivo. (A) Cell cycle analysis using BrdU incorporation (upper panels) and PI staining for DNA content (lower panels) was performed of p53 wild-type (Tp53 Wt) and (Tp53−/−) Eμ-Myc lymphoma cells following 24-hour treatment with vehicle, 100 nM CX-5461, 30 nM AZD7762 (CHK1/2i) or combined 100 nM CX-5461/30 nM CHK1/2i. Analysis was performed as in Figure 2A (representatives of n = 3). (B) Western blotting analysis of phosphorylated and total protein levels of p53 and CHK1 in Tp53 Wt and Tp53−/− Eμ-Myc lymphoma cells following 30 min treatment with CX-5461 as indicated. Actin levels were used as a loading control. (C) Percentages of live Tp53-/- Eμ-Myc lymphoma cells (Annexin V –ve/ PI –ve) cells treated as in (A) (n = 3), error bars represent mean ± s.e.m., **p-value < 0.01 compared to corresponding CX-5461 treated samples. (D) CX-5461 combination with CHK1/2i leads to improved therapeutic benefit in treating transplanted Tp53−/− Eμ-Myc lymphoma cells in vivo. Kaplan-Meier curves showing increased survival of mice transplanted with Tp53−/− Eμ-Myc lymphoma (clone 3228) treated daily with 20 mg/kg AZD7762 (CHK1/2i) every weekday, CX-5461 at 30 mg/kg every third day or combined CX-5461+CHK1/2i (***p < 0.0001; n = 6 in every treatment group). Treatment period is indicated by the grey area.

Journal: Oncotarget

Article Title: Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

doi: 10.18632/oncotarget.10452

Figure Lengend Snippet: Figure 5: CX-5461 combination with a dual CHK1/CHK2 inhibitor induces cancer cell death of Tp53-null (Tp53−/−) Eμ-Myc lymphoma cells in vitro and in vivo. (A) Cell cycle analysis using BrdU incorporation (upper panels) and PI staining for DNA content (lower panels) was performed of p53 wild-type (Tp53 Wt) and (Tp53−/−) Eμ-Myc lymphoma cells following 24-hour treatment with vehicle, 100 nM CX-5461, 30 nM AZD7762 (CHK1/2i) or combined 100 nM CX-5461/30 nM CHK1/2i. Analysis was performed as in Figure 2A (representatives of n = 3). (B) Western blotting analysis of phosphorylated and total protein levels of p53 and CHK1 in Tp53 Wt and Tp53−/− Eμ-Myc lymphoma cells following 30 min treatment with CX-5461 as indicated. Actin levels were used as a loading control. (C) Percentages of live Tp53-/- Eμ-Myc lymphoma cells (Annexin V –ve/ PI –ve) cells treated as in (A) (n = 3), error bars represent mean ± s.e.m., **p-value < 0.01 compared to corresponding CX-5461 treated samples. (D) CX-5461 combination with CHK1/2i leads to improved therapeutic benefit in treating transplanted Tp53−/− Eμ-Myc lymphoma cells in vivo. Kaplan-Meier curves showing increased survival of mice transplanted with Tp53−/− Eμ-Myc lymphoma (clone 3228) treated daily with 20 mg/kg AZD7762 (CHK1/2i) every weekday, CX-5461 at 30 mg/kg every third day or combined CX-5461+CHK1/2i (***p < 0.0001; n = 6 in every treatment group). Treatment period is indicated by the grey area.

Article Snippet: AZD7762 (Medchem Express) was delivered intraperitoneally in 10.3% -hydroxypropylβ-cyclodextrin in 0.9% saline at 20 mg/kg daily on weekdays.

Techniques: In Vitro, In Vivo, Cell Cycle Assay, BrdU Incorporation Assay, Staining, Western Blot, Control